Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric and AYA ALL therapy. Watch experts provide guidance on the modern use of asparaginase therapy and share tactics for addressing real-world barriers to effective care, including hypersensitivity, silent inactivation